- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05121779
Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT
November 4, 2021 updated by: Peking Union Medical College Hospital
68Ga-fibroblast activating protein inhibitors(FAPI) has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as inflammatory bowel disease.
And it might be more sensitive than FDG in detecting a certain type of inflammations according to our preliminary research.
Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of Pulmonary fibrosis than 18F-FDG PET/CT.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease.Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is destroyed, which leads to decreased lung compliance, disrupted gas exchange, and ultimately respiratory failure and death.Pulmonary fibrosis is diagnosed by identification of a pattern of usual interstitial pneumonia on the basis of radiological or histological criteria in patients without evidence of an alternative cause.
Activated fibroblasts are crucial for fibrotic processes in Pulmonary fibrosis.
68Ga-FAPI has been developed as a tumortargeting agent as fibroblast activation protein is overexpressed in cancerassociated fibroblasts and inflammation.
Recently,a study shows that FAPI-PET/CT imaging is a promising new imaging modality for Pulmonary fibrosis.This head-to-head comparisons aims to evaluate the severity of pulmonary fibrosis and the therapy response of 68Ga-FAPI-04 compared with 18F-FDG in the same group of pulmonary fibrosis patients.
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Peking Union Medical College Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- suspected or confirmed pulmonary fibrosis patients;
- signed written consent.
Exclusion Criteria:
- pregnancy;
- breastfeeding;
- known allergy against FAPI
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT
All patients diagnosed with Lung fibrosis underwent 68Ga-FAPI PET/CT and 18F-FDG PET/CT.
|
Intravenous injection of one dosage of 18.5-22.2MBq
(0.5-0.6 mCi)/Kg 68Ga-FAPI.
Tracer doses of 68Ga-FAPI will be used to image lesions of pulmonary fibrosis by PET/CT.
Other Names:
Intravenous injection of one dosage of 4.44-5.55
MBq(0.12-0.15mCi)/Kg
18F-FDG.
Tracer doses of 18F-FDG will be used to image lesions of pulmonary fibrosis by PET/CT.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic value
Time Frame: through study completion, an average of 1 year
|
Sensitivity and Specificity of 68Ga-FAPI PET/CT for Lung fibrosis in comparison with 18F-FDG PET/CT
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
FAPI expression and SUV
Time Frame: through study completion, an average of 1 year
|
Correlation between FAPI expression and SUV in PET
|
through study completion, an average of 1 year
|
therapy response
Time Frame: through study completion, an average of 1 year
|
Decrease of 68Ga-FAPI PET/CT SUVmax after therapy
|
through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
December 1, 2021
Primary Completion (Anticipated)
December 1, 2022
Study Completion (Anticipated)
December 1, 2023
Study Registration Dates
First Submitted
November 4, 2021
First Submitted That Met QC Criteria
November 4, 2021
First Posted (Actual)
November 16, 2021
Study Record Updates
Last Update Posted (Actual)
November 16, 2021
Last Update Submitted That Met QC Criteria
November 4, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PUMCH-NM-FAPI-PF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingIdiopathic Pulmonary Fibrosis | Pulmonary Disease | Pulmonary MedicineFrance
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Centre Hospitalier Universitaire de NiceRecruitingPulmonary Disease, Chronic Obstructive | Interstitial Pulmonary FibrosisFrance
-
Boehringer IngelheimNot yet recruitingIdiopathic Pulmonary Fibrosis | Progressive Pulmonary Fibrosis
Clinical Trials on 68Ga-FAPI
-
Affiliated Hospital of Jiangnan UniversityRecruiting
-
RenJi HospitalRecruitingOvarian Cancer | Epithelial Ovarian Cancer | Positron Emission Tomography | 68Ga-FAPIChina
-
Peking Union Medical College HospitalRecruitingMetastatic Adenoid Cystic Carcinoma | 68Ga-FAPI PET/CTChina
-
Xiangya Hospital of Central South UniversityCompleted
-
Peking Union Medical College HospitalRecruiting
-
First Affiliated Hospital of Fujian Medical UniversityCompletedTumor Positron-Emission TomographyChina
-
The First Affiliated Hospital of Xiamen UniversityRecruiting177Lu-DOTA-FAPI | 68Ga-DOTA-FAPI | TheranosticChina
-
Peking Union Medical College HospitalRecruiting
-
First Affiliated Hospital of Fujian Medical UniversityRecruitingFibrosis | Positron-Emission TomographyChina
-
The First Affiliated Hospital of Xiamen UniversityRecruiting